CA-A Cancer Journal for Clinicians

Papers
(The TQCC of CA-A Cancer Journal for Clinicians is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Minority groups underrepresented in hematologic cancer trials13919
Evolution of community outreach and engagement at National Cancer Institute‐Designated Cancer Centers, an evolving journey12594
Breast cancer in a transgender man11340
Cancer treatment and survivorship statistics, 20256126
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies1986
1954
Issue Information1569
Near majority of adults favor R ratings for films with smoking644
Cancer care for transgender and gender‐diverse people: Practical, literature‐driven recommendations from the Multinational Association of Supportive Care in Cancer502
Cancer statistics 2024: All hands on deck455
Highlighting American Cancer Society‐funded research in CA: A Cancer Journal for Clinicians371
Breast cancer: The good, the bad, and an important call to effective risk reduction strategies313
Most patients with cancer are not undergoing germline genetic testing310
Multicancer detection tests: What we know and what we don’t know282
Reirradiation: Standards, challenges, and patient‐focused strategies across tumor types276
Current treatment and future directions in the management of anal cancer248
More care needed for cancer caregivers241
212
Issue Information189
Underrepresentation of Hispanic women in science, technology, engineering, mathematics, and medicine172
Clinical practice guideline and expert consensus recommendations for rehabilitation among children with cancer: A systematic review168
Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians164
Treating EGFR‐mutant nonsmall cell lung cancer is no longer a one‐size‐fits‐all approach156
Reduced‐volume radiotherapy versus conventional‐volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open‐label, noninferiority, multicenter, randomized phase 3 trial144
The evolving landscape of tissue‐agnostic therapies in precision oncology142
Health insurance status and cancer stage at diagnosis and survival in the United States138
Does distance deter male fertility preservation?107
Study identifies risk factors that may lead to secondary cancers103
Overlooked barriers to implementation of geriatric assessment89
Interventional gastroenterology in oncology82
Multidisciplinary management in the treatment of intrahepatic cholangiocarcinoma80
Lung cancer screening guidelines: Smoking matters, not quitting79
Medicaid expansion increases survival for patients with cancer77
The contemporary management of cancers of the sinonasal tract in adults74
Cancer survivors at greater risk for bone fractures late in life73
Issue Information73
Screening for lung cancer70
Bilateral mastectomy may not reduce mortality risk69
Issue Information69
Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance68
From medical student to Editor: A note of thanks67
Breast Cancer Statistics, 202263
Chemotherapy‐induced taste changes affect nutrition, quality of life58
Issue Information55
Prevention of device‐related infections in patients with cancer: Current practice and future horizons53
Clinical management of metastatic colorectal cancer in the era of precision medicine39
Cancer treatment and survivorship statistics, 202239
Better communication is key for quality‐of‐life improvement in low‐income and minority patients37
American Cancer Society nutrition and physical activity guideline for cancer survivors37
Issue Information35
35
33
A pan‐tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors32
Is active surveillance an alternative to surgery for some patients with esophageal cancer?32
Cancer misinformation on social media29
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries29
Key issues face AI deployment in cancer care27
26
0.68841505050659